Royal Marsden NHS Foundation Trust
π¬π§United Kingdom
- Country
- π¬π§United Kingdom
- Ownership
- Private, Subsidiary
- Employees
- -
- Market Cap
- -
A Retrospective Study of Toxicity and Outcome of High Dose Chemotherapy With Autologous Stem Cell Transplant in Patients With Non-Hodgkin Lymphoma (NHL).
Completed
- Conditions
- First Posted Date
- 2006-03-10
- Last Posted Date
- 2010-01-12
- Lead Sponsor
- Royal Marsden NHS Foundation Trust
- Target Recruit Count
- 152
- Registration Number
- NCT00301288
- Locations
- π¬π§
Royal Marsden NHS trust, Sutton, Surrey, United Kingdom
A Randomized Trial of Human Growth Hormone (hGH) vs Placebo in Intensively Treated Haemato-Oncology Patients.
Phase 2
Completed
- Conditions
- First Posted Date
- 2006-03-09
- Last Posted Date
- 2006-10-13
- Lead Sponsor
- Royal Marsden NHS Foundation Trust
- Target Recruit Count
- 150
- Registration Number
- NCT00300664
A Multicenter, Open-Label Continuation Trial Evaluating the Tolerability and Activity of Depsipeptide (FK228) in Patients That Have Completed a Prior Clinical Study With Depsipeptide.
Phase 2
- Conditions
- First Posted Date
- 2006-03-06
- Last Posted Date
- 2006-03-06
- Lead Sponsor
- Royal Marsden NHS Foundation Trust
- Target Recruit Count
- 8
- Registration Number
- NCT00299351
Modelling Internal Hepatic Movement With an External Abdominal Marker
- First Posted Date
- 2006-03-06
- Last Posted Date
- 2010-01-12
- Lead Sponsor
- Royal Marsden NHS Foundation Trust
- Target Recruit Count
- 10
- Registration Number
- NCT00299299
- Locations
- π¬π§
Royal Marsden Hospital, Chelsea, United Kingdom
Dual Time Point PET Imaging in Lymphoma
- Conditions
- First Posted Date
- 2006-02-28
- Last Posted Date
- 2006-10-11
- Lead Sponsor
- Royal Marsden NHS Foundation Trust
- Registration Number
- NCT00297557
A Single-arm Phase II Study of Alemtuzumab in Combination With High-dose Methylprednisolone in CLL Patients With p53 Deletion
Phase 2
Completed
- Conditions
- First Posted Date
- 2006-02-16
- Last Posted Date
- 2009-12-16
- Lead Sponsor
- Royal Marsden NHS Foundation Trust
- Registration Number
- NCT00292760
Combining Erlotinib Plus Bevacizumab and Gemcitabine Plus Capecitabine to Treat Advanced Pancreatic Cancer
Phase 1
Completed
- Conditions
- First Posted Date
- 2005-12-01
- Last Posted Date
- 2016-10-14
- Lead Sponsor
- Royal Marsden NHS Foundation Trust
- Target Recruit Count
- 44
- Registration Number
- NCT00260364
- Locations
- π¬π§
The Royal Marsden Foundation Hospital NHS Trust, London and Surrey, London, United Kingdom
Pre-operative Epirubicin, Cisplatin, and Capecitabine in Patients With Newly Diagnosed Localised Oesophageal Adenocarcinoma
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2009-12-16
- Lead Sponsor
- Royal Marsden NHS Foundation Trust
- Target Recruit Count
- 80
- Registration Number
- NCT00220103
- Locations
- π¬π§
Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom
Molecular Markers of Prognosis in Colorectal Cancer Patients
Completed
- Conditions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2013-05-31
- Lead Sponsor
- Royal Marsden NHS Foundation Trust
- Target Recruit Count
- 103
- Registration Number
- NCT00220142
- Locations
- π¬π§
Royal Marsden Hospital, Sutton, Surrey, United Kingdom
A Phase II Trial Evaluating Irinotecan Plus 5FU/LV in Patients With Relapsed/Refractory Upper GI Tumours
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2013-05-31
- Lead Sponsor
- Royal Marsden NHS Foundation Trust
- Target Recruit Count
- 65
- Registration Number
- NCT00220064
Β© Copyright 2024. All Rights Reserved by MedPath